A comprehensive view of amgen inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Japan joins US, EU in approving AstraZeneca’s injectable asthma drug Tezspire tezepelumab, developed with Amgen; Tezspire treats severe, refractory bronchial asthma that can't be controlled with inhaled corticosteroids, long-term maintenance therapies
Published: September 28, 2022 by SeeNews Pharmaceuticals
Zacks names Merck, UnitedHealth and Amgen among best stocks in S&P 500; earnings growth for 2022 estimated at 21.8% for Merck, at 14.9% for UnitedHealth, and at 2% for Amgen
Published: September 26, 2022 by Zack's Commentary
US Solicitor General suggests Supreme Court turn down Amgen’s request to hear PCSK9 patent case with Sanofi and Regenron; appeals court ruling called Amgen’s claims invalid because it would take ‘undue experimentation’ to enable their full scope
Published: September 26, 2022 by FiercePharma
Executive Perspective: Amgen CEO says newly-passed Inflation Reduction Act may make it difficult for small, midsized biotechs to continue on their own without merging with another company; CEO believes new law will stymie innovation
Published: September 16, 2022 by FiercePharma
Fitch affirms Amgen's issuer default rating at BBB+ with stable rating outlook, says ChemoCentryx acquisition makes strategic sense, as it adds to Amgen's current presence in autoimmune diseases, inflammatory disorders and cancer
Published: August 17, 2022 by ENP Newswire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count